Cargando…

Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases

Background: Limited pharmacotherapy and the failure of conventional treatments in complex pathologies in children lead to increased off-label use of rituximab. We aimed to characterize the time course of CD19+ B lymphocytes (CD19+) under treatment with intravenous rituximab in children with neurolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riva, Natalia, Brstilo, Lucas, Sancho-Araiz, Aymara, Molina, Manuel, Savransky, Andrea, Roffé, Georgina, Sanz, Marianela, Tenembaum, Silvia, Katsicas, Maria M., Trocóniz, Iñaki F., Schaiquevich, Paula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674351/ https://www.ncbi.nlm.nih.gov/pubmed/38004515 http://dx.doi.org/10.3390/pharmaceutics15112534

Ejemplares similares

Intensive Safety Monitoring of Rituximab (Biosimilar Novex(®) and the Innovator) in Pediatric Patients With Complex Diseases
por: Riva, Natalia, et al.
Publicado: (2022)

The Role of Mathematical Models in Immuno-Oncology: Challenges and Future Perspectives
por: Sancho-Araiz, Aymara, et al.
Publicado: (2021)

Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases
por: Pan, Shan, et al.
Publicado: (2019)

Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment
por: Sancho-Araiz, Aymara, et al.
Publicado: (2023)

Neuromyelitis optica associated with systemic autoimmune diseases in children
por: Russo, RA, et al.
Publicado: (2008)

Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors
por: Sancho-Araiz, Aymara, et al.
Publicado: (2021)

Use of rituximab in paediatric nephrology
por: Sinha, Rajiv, et al.
Publicado: (2021)

Reconstitution of the adult B cell repertoire after treatment with rituximab
por: Sanz, Iñaki, et al.
Publicado: (2005)

Real-World Evidence of Factors Affecting Cannabidiol Exposure in Children with Drug-Resistant Developmental and Epileptic Encephalopathies
por: Brstilo, Lucas, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
por: Centanni, Maddalena, et al.
Publicado: (2019)

Rituximab pediatric drug development: Pharmacokinetic and pharmacodynamic modeling to inform regulatory approval for rituximab treatment in patients with granulomatosis with polyangiitis or microscopic polyangiitis
por: Jamois, Candice, et al.
Publicado: (2022)

Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology()
por: Barker, Charlotte I.S., et al.
Publicado: (2014)

Pharmacokinetic Pharmacodynamic Modelling Contributions to Improve Paediatric Anaesthesia Practice
por: Morse, James D., et al.
Publicado: (2022)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

The Clinical Spectrum of Autoimmune-Mediated Neurological Diseases in Paediatric Population
por: Lubarski, Karol, et al.
Publicado: (2022)

Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases
por: Memon, Anza B., et al.
Publicado: (2018)

The training & organisation of paediatric neurology in Europe
por: Zuberi, Sameer M.
Publicado: (2020)

Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab
por: Nytrova, Petra, et al.
Publicado: (2023)

Improving access for Urgent patients in Paediatric Neurology
por: Mohamed, Khalid, et al.
Publicado: (2017)

Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic
por: Richter, Maximilian, et al.
Publicado: (2016)

Phase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma
por: Shi, Yuankai, et al.
Publicado: (2021)

Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives
por: Hartinger, Jan Miroslav, et al.
Publicado: (2022)

Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling
por: Martin-Romano, Patricia, et al.
Publicado: (2019)

Recognition and prevention of neurological complications in paediatric cardiac surgery
por: Kirkham, Fenella J
Publicado: (2000)

Pattern of Paediatric Neurological Disorders in Port Harcourt, Nigeria
por: Frank-Briggs, A. I., et al.
Publicado: (2011)

Medicine: Analytical Reviews of General Medicine, Neurology, Pædiatrics
Publicado: (1932)

Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic‐pharmacodynamic analysis of cinacalcet
por: Chen, Ping, et al.
Publicado: (2019)

Rituximab for Autoimmune Encephalitis with Epilepsy
por: Kurukumbi, Mohankumar, et al.
Publicado: (2020)

Neurology
por: Barone, Georgina
Publicado: (2012)

A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis
por: Cattrall, J. W. S., et al.
Publicado: (2019)

Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions
por: Krysko, Kristen M., et al.
Publicado: (2019)

Encephalitis as a neurological manifestation of COVID-19()
por: Lozano Gómez, Herminia, et al.
Publicado: (2021)

Paediatric headache management: comparing secondary general paediatric clinics to a tertiary paediatric neurology clinic, using national quality standards
por: Liew, Elizabeth Anastasia Zi Yin, et al.
Publicado: (2023)

Disseminated encephalomyelitis in children
por: Tenembaum, Silvia N.
Publicado: (2008)

Acute disseminated encephalomyelitis
por: Tenembaum, Silvia N.
Publicado: (2013)

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease
por: Tieu, Joanna, et al.
Publicado: (2021)

Case Report: Multisystem Autoimmune and Overlapping GAD65-Antibody-Associated Neurological Disorders With Beneficial Effect of Epilepsy Surgery and Rituximab Treatment
por: Dimova, Petia, et al.
Publicado: (2022)

Rituximab Monotherapy versus Rituximab and Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy
por: Maleki, Arash, et al.
Publicado: (2022)

Personalised medicine in paediatrics: individualising treatment in children with rare neurological diseases
por: Scarpa, Maurizio, et al.
Publicado: (2011)

MR imaging findings in some rare neurological complications of paediatric cancer
por: Okabe, Tetsuhiko, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8db59sve31r8vdakpfufnfa3kt